Life Science Investing Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease
Life Science Investing Bristol Myers Squibb Builds on Eliquis® Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu®
Life Science Investing Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
Life Science Investing Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
Life Science Investing Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
pharmaceutical investing SELLAS Life Sciences Group and Cancer Center to Study Galinpepimut-S in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma
Providence Gold Mines: Unlocking Untapped, High-grade Gold Deposits in the historic Mother Lode Gold Belt in California
